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Most therapeutic agents are excluded from entering the central
nervous system by the blood–brain barrier (BBB). Receptor medi-
ated transcytosis (RMT) is a common mechanism used by proteins,
including transferrin (Tf), to traverse the BBB. Here, we prepared
Tf-containing, 80-nm gold nanoparticles with an acid-cleavable link-
age between the Tf and the nanoparticle core to facilitate nano-
particle RMT across the BBB. These nanoparticles are designed to
bind to Tf receptors (TfRs) with high avidity on the blood side of the
BBB, but separate from their multidentate Tf–TfR interactions upon
acidification during the transcytosis process to allow release of the
nanoparticle into the brain. These targeted nanoparticles show in-
creased ability to cross an in vitro model of the BBB and, most
important, enter the brain parenchyma of mice in greater amounts
in vivo after systemic administration compared with similar high-
avidity nanoparticles containing noncleavable Tf. In addition, we
investigated this design with nanoparticles containing high-affinity
antibodies (Abs) to TfR. With the Abs, the addition of the acid-cleav-
able linkage provided no improvement to in vivo brain uptake for
Ab-containing nanoparticles, and overall brain uptake was de-
creased for all Ab-containing nanoparticles compared with Tf-con-
taining ones. These results are consistent with recent reports of
high-affinity anti-TfR Abs trafficking to the lysosome within BBB
endothelium. In contrast, high-avidity, Tf-containing nanoparticles
with the acid-cleavable linkage avoid major endothelium retention
by shedding surface Tf during their transcytosis.
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The inability of drugs to cross the blood–brain barrier (BBB) isone of the major impairments to developing treatments for
neurological diseases. This highly restrictive, physiologic barrier
excludes 98% of small-molecule drugs and ∼100% of large-molecule
drugs from reaching the central nervous system (CNS) from
blood circulation (1). Many methods to bypass the BBB have
been investigated, such as transient disruption of the BBB, in-
hibition of efflux pumps, or transport using endogenous trans-
cytosis systems, including receptor-mediated transcytosis (2–4).
Transferrin receptor (TfR) has been one of the primary tar-
gets investigated for receptor-mediated transcytosis across the
BBB because of its high expression on BBB endothelium (5).
Anti-TfR antibody–drug conjugates have received the most at-
tention because of their ability to bind TfR with high affinity
without interfering with endogenous transferrin (Tf) (6–8). De-
spite the perceived potential of anti-TfR antibody–drug conju-
gates, a BBB-permeable drug using this approach has yet to
reach the clinic. Yu et al. showed that anti-TfR Abs enter the
brain in greater numbers when their affinity to TfR is reduced
(9). Follow-up work from the same group showed that high-
affinity, bispecific anti-TfR Abs preferentially trafficked to the
lysosome within BBB endothelium, rather than transcytosing,
whereas low-affinity Abs did not (10). A similar effect was seen
with a divalent anti-TfR Ab, which entered the lysosome in
significantly greater amounts than the monovalent variant (11).
Recently, our group demonstrated that Tf-containing, 80-nm
gold nanoparticles (AuNP) with near-neutral zeta potentials are
capable of accessing the brain parenchyma from the blood when
their avidity to TfR is appropriately tuned (12). If the avidity is too
high, the nanoparticles remain strongly associated with the en-
dothelial cells of the BBB, whereas nanoparticles of lower avidity
are able to release into the brain after transcytosis. Although the
lower-avidity nanoparticles showed the greatest ability to enter the
brain, the higher-avidity nanoparticles still were able to cross
the BBB in greater amounts than non-Tf-containing nanoparticles.
As with Ab BBB transcytosis, the nanoparticles with reduced
avidity to TfR showed the greatest ability to cross the BBB. A
major obstacle to translating these agents to viable therapeutics
is the need to dose very high quantities in the blood for an ap-
preciable amount of drug to reach the CNS (6, 9, 12). We
attempted to increase the ability of Tf-containing nanoparticles
to reach the brain parenchyma by incorporating a small chemical
linker between the Tf and AuNP cores that cleaves at mildly
acidic pH. This design provides for high-avidity interactions with
TfR at the blood side of the BBB to enable practical, systemic
dosing amounts. Then, as the targeted nanoparticles transcytose,
we use the drop in pH (13, 14) the bound nanoparticles would
experience during the transcytosis process to trigger the cleavage
of the linkage between the Tf and the nanoparticle core. Thus,
when the transcytosing vesicle reaches the brain, the nanoparticles
will no longer be bound and can be released into the parenchyma.
With this design, the nanoparticle will retain high-avidity in-
teractions with TfR on the blood side of the BBB, but not be re-
stricted once within the endothelium (Fig. 1A). Recently, in vitro
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results using an anti-TfR Ab with reduced affinity at pH 5.5
showed the ability to transcytose across hCMEC/D3 cells, whereas
Abs with high affinity independent of pH were trafficked to the
lysosome (15), suggesting vesicle trafficking may be affected by a
particular targeting ligand. Thus, we also investigated whether Tf,
the natural ligand for the TfR, and anti-TfR Abs behaved dif-
ferently when used as the targeting agents for the nanoparticles.
Our results show a nearly threefold increase in the ability of high-
avidity nanoparticles to reach the brain parenchyma in vivo after
incorporation of an acid-cleavable, diamino ketal (DAK) linker.
We also observed a direct relationship between brain penetration
of nanoparticles and surface Tf-DAK content. Furthermore, no
improvement was seen in the ability for anti-TfR Ab-containing
nanoparticles to cross the BBB with addition of the DAK linker,
suggesting there are significant differences in their intracellular
trafficking compared with that of Tf-containing nanoparticles.
Results
Synthesis and Characterization of Acid-Cleavable, Ligand–PEG Conjugates.
The acid-sensitive DAK [2,2-bis(aminoethoxy)propane] moiety
was added to a 5-kDa polyethylene glycol (PEG), followed by
conjugation of the polymer to either human holo-Tf or R17217
anti-mouse TfR Ab (Fig. 1B and SI Appendix, Fig. S1). DAK was
chosen because its reported hydrolysis half-life is 60 min at
pH 5.5 but more than 24 h at pH 7.4 and 37 °C (16). These
hydrolysis kinetics should provide sufficient Ligand-DAK-PEG
stability for the Tf/Ab to remain associated with the nanoparticle
while it is circulating in the blood, but cleave in the acidic vesicles
during the transcytosis process, so that the majority of the ligand
disassociates from the nanoparticle core during that time. The
stability of the Tf-DAK-PEG (Tf-C) conjugate was monitored by
MALDI-TOF and found to release Tf within 2 h once placed in
pH 5.5 buffer at 37 °C (SI Appendix, Fig. S2A). The conjugate
remained virtually unchanged at pH 8 after 2 h and could still be
detected after 24 h (SI Appendix, Fig. S2B).
Tf/Ab-DAK-PEG-Containing Nanoparticles Have Decreased Avidity to
TfR After Exposure to Mildly Acidic pH. To prepare the targeted
nanoparticles, various quantities of either cleavable (Tf-C/Ab-C)
or noncleavable (Tf-N/Ab-N) ligand were added to 50-nm
AuNPs, followed by an addition of excess, nonfunctionalized
PEG (mPEG) (Fig. 1C). AuNPs were chosen for the utility of
their detection within biological systems through transmission
electron microscopy, inductively coupled plasma mass spec-
trometry (ICP-MS), or silver enhancement. Nanoparticles were
prepared in this manner to preserve the characteristics we found
useful in our previous formulations, which showed that ∼80-nm
nanoparticles with near-neutral zeta potentials (<−15 mV) best
enter the brain (12). Also, sub-100-nm nanoparticles with dense
PEG coating and near-neutral zeta potentials have shown the
ability to diffuse throughout the brain’s extracellular space (17).
All nanoparticle formulations prepared here had hydrodynamic
diameters near 80 nm, as measured by dynamic light scattering,
and zeta potentials between −11 and −5 mV when measured in
1 mM KCl (Table 1).
An in vitro, cell-binding assay was performed using the
Neuro2A mouse brain endothelial cell line to determine the avidity
of the nanoparticles to mouse TfRs. Cells were incubated with
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Fig. 1. (A) Proposed mechanism of transcytosis for Tf-containing nanoparticles with an acid-cleavable linkage. After endocytosis, rapid acidification of the
endosome causes separation of the Tf ligand from the nanoparticle core, allowing free movement of the nanoparticle into the brain parenchyma once
transcytosis is complete. (B) Preparation of acid-cleavable DSS-DAK-PEG-OPSS and addition to the targeting ligand (Tf/Ab) to create the cleavable conjugate.
(C) Addition of the Tf/Ab-DAK-PEG-OPSS ligand followed by excess mPEG-SH to prepare targeted gold nanoparticles. n ∼ 120 for 5-kDa PEG.
Table 1. Nanoparticle formulations and characteristics
Formulation
Nanoparticle
diameter, nm Zeta potential, mV Kd, nM
mPEG 75.1 ± 2.4 −5.75 ± 4.12 N.D.
20Tf-N 79.1 ± 0.9 −5.77 ± 2.21 0.408
200Tf-N 78.1 ± 6.2 −7.78 ± 3.73 0.029
20Tf-C 75.7 ± 4.4 −11.25 ± 1.81 0.788
120Tf-C 77.2 ± 0.2 −7.93 ± 0.60 0.096
200Tf-C 73.6 ± 1.6 −7.47 ± 3.12 0.030
2Ab-N 76.1 ± 4.3 −6.26 ± 2.00 0.441
10Ab-N 84.4 ± 6.9 −8.83 ± 2.19 0.039
2Ab-C 72.9 ± 4.9 −6.36 ± 2.44 0.619
10Ab-C 77.4 ± 1.9 −5.10 ± 2.31 0.021
The number in the formulation name indicates the number of ligands per
nanoparticle, -N indicates noncleavable PEG conjugate, and -C indicates
cleavable PEG conjugate. Data shown for hydrodynamic diameter and zeta
potential are the average of 5 measurements ±1 SD. N.D. = not determined.
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increasing quantities of nanoparticles. Then the bound nano-
particles were quantified by silver enhancement, a highly sensitive
AuNP detection method (18). The binding data were fit to a
Langmuir binding isotherm to calculate Kd (SI Appendix, Fig. S3).
The binding avidity was directly dependent on the ligand content of
the nanoparticle (Table 1), as we have shown previously (12).
Also, by increasing the quantity of Tf contained on the nano-
particle, avidities similar to those of the nanoparticles containing
the R17217 Ab with lower protein numbers could be obtained.
The cell-binding assay was repeated for the 200Tf-C and 10Ab-C
formulations after incubating the particles at pH 5.5 for 4 h at
37 °C. Both formulations showed lower avidity to TfR (Kd = 1.16 nM
for 200Tf-C; Kd = 0.512 nM for 10Ab-C) after exposure to decreased
pH, indicating loss of the surface ligand (Fig. 2).
High-Avidity Tf-DAK-PEG-Containing Nanoparticles Cross an in Vitro
Model of the BBB Rapidly and in the Greatest Amounts. To assess
how the addition of the DAK linker may affect the ability of the
targeted nanoparticles to cross the BBB in vivo, we used the
bEnd.3 cell line, an immortalized mouse brain endothelial line,
in a commonly used in vitro model of the BBB (19). Nano-
particles were added to the apical compartment of bEnd.3-
coated transwells in serum-free DMEM and allowed to cross the
cellular border over the course of 8 h. The full volume of the
basal compartment was removed and replaced by fresh, serum-
free DMEM at various points. These samples were then mea-
sured for gold content using ICP-MS.
After 8 h, the 200Tf-C formulation showed the greatest capacity
to cross the BBB model membrane (Fig. 3A). These nanoparticles
reach the basal compartment at a 10-fold increased quantity
compared with the 200Tf-N formulation. All Tf-containing for-
mulations reveal decreased ability to cross the bEnd.3 cells when
coincubated with serum concentrations of Tf, indicating specific
binding of TfR is responsible for crossing (SI Appendix, Fig. S4).
Unlike the high-avidity Tf-C formulations, the Ab-C formulations
did not show a significant difference in basal well accumulation
compared with Ab-N. In fact, all Ab-containing formulations
showed similar or less crossing than nontargeted mPEG particles
(SI Appendix, Fig. S5). After the 8-h incubation, the cells exposed
to the high-avidity formulations (200Tf-N, 200Tf-C, 10Ab-N) were
lysed, and intracellular gold content was measured (SI Appendix,
Fig. S6). The 10Ab-N formulation had significantly more gold
within the cells compared with 200Tf-C, consistent with high-
affinity Abs being primarily retained by endothelial cells rather
than transcytosing.
Interestingly, all three Tf-C formulations underwent the ma-
jority of their total crossing within the first 60 min after introduction
Fig. 2. Tf/Ab-DAK-PEG-containing nanoparticles have decreased avidity for
mouse TfR after exposure to mildly acidic pH. (A) Nanoparticle binding to
Neuro2A cells for 200Tf-C formulation after exposure to either neutral or
acidic pH. 200Tf-C nanoparticles bind with high avidity (Kd = 0.040 nM) when
kept at pH 7.4, but avidity is reduced after incubating nanoparticles at
pH 5.5 (Kd = 1.16 nM). (B) The same effects are observed with 10Ab-C for-
mulation (Kd = 0.021 nM at pH 7.4; Kd = 0.512 nM after pH 5.5), as in A with
200Tf-C. Curves are fitted Langmuir binding isotherms.
Fig. 3. 120Tf-C and 200Tf-C nanoparticles cross an in vitro model of the BBB
in greater amounts than 20Tf-N and 200Tf-N. (A) Percentage of injected
nanoparticles reaching the basal well of bEnd.3 coated transwells 8 h after
introduction. 120Tf-C and 200Tf-C show greater ability to cross the trans-
wells compared with 200Tf-N, whereas both Ab-C formulations did not
show a significant increase compared with equivalent Ab-N formulations.
(B) Tf-containing nanoparticles crossing the model BBB over time. All Tf-C
formulations show the majority of crossing within the first 2 h (SI Appendix,
Table S1). The average of three wells for each group is shown (except for
20Tf-C, n = 4). Error bars given are SE. *P < 0.001.
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(Fig. 3B). The Tf-N formulations, conversely, showed slower basal
well accumulation during the 8 h (SI Appendix, Table S1). For ex-
ample, by 60 min, only 18% of the total 20Tf-N quantity reached
the basal well compared with 61% of the total 20Tf-C. AuNPs with
diameters between 50 and 100 nm have been shown to rapidly
sediment within in vitro systems using an upright cell orientation
(20). This causes the particle concentration at the cell surface to be
higher than the rest of the solution. Because each Tf-C formulation
crossed the bEnd.3 cells rapidly after introduction, these results
suggest that these nanoparticles are undergoing transcytosis upon
initial contact with the cells, whereas the Tf-N formulations may
have a larger portion recycled back to the cell surface or retained by
the cells. Also, the 120Tf-C and 200Tf-C formulations reached near
maximum crossing within 2 h (93% and 94% of total, respectively)
compared with 200Tf-N (47%). These data indicate that the high-
avidity, cleavable nanoparticles may be saturating the transcytosis
pathway within 2 h of exposure.
Addition of DAK Linkage Increases the Ability of High-Avidity,
Tf-Containing Nanoparticles to Enter the Brain, but Does Not Affect
Those with Anti-TfR Abs. Nanoparticles of each formulation listed
in Table 1 were injected into BALB/c mice and assessed for their
ability to enter the brain parenchyma. A total of three mice were
used for each formulation. Nanoparticles were systemically ad-
ministered by injection via the lateral tail vein and allowed to
circulate for 12 h. Mice were then euthanized, and the brains
resected and processed for histological examination. The loca-
tions of nanoparticles within the brain were determined using
silver enhancement. Deposition of metallic silver onto gold nano-
particles allows individual nanoparticles to become visible by light
microscopy. Nanoparticles present within the brain parenchyma
were manually counted in 40 images per mouse. The median
number of nanoparticles in the parenchyma for each group is
shown in Fig. 4. As with the in vitro experiment, the 200Tf-C
formulation showed the highest penetration into the brain, and a
significantly higher quantity compared with 200Tf-N. Also, in-
corporation of the cleavable link did not increase the ability of
either Ab-C formulation to enter the parenchyma. The 20Tf-C
formulation did not significantly differ from 20Tf-N, but more
nanoparticles localized into the brain as the surface content of
Tf-DAK increased. The 120Tf-C and 200Tf-C nanoparticles
entered the brain best, but did not significantly differ from one
another (they have relatively similar Kd values; Table 1). Results
from mPEG, 20Tf-N, and 200Tf-N are essentially the same as we
reported previously, using formulations of those type (12), and
indicate the good reproducibility of our methods. The 20Tf-N
formulation reached the parenchyma in significantly higher
amounts than 200Tf-N (SI Appendix, Table S2), indicating the
high-avidity Tf-containing nanoparticles are retained and/or stuck
to the endothelium without the presence of the cleavable linker.
Sample images for each formulation are shown in Fig. 5. Fully
magnified images are available in SI Appendix, Figs. S8–S11. All
slides were silver-stained simultaneously with a blank brain (no
AuNPs injected) to assess for any nonspecific staining [some areas
of nonspecific silver stain were observed in the blank sample (SI
Appendix, Fig. S7), and similar staining patterns observed in
AuNP-containing samples were not included in the analysis].
Discussion
Here, we show that high-avidity, Tf-containing nanoparticles can
enter the brain in vivo in mice from systemic administrations if Tf
is attached to the nanoparticle through an acid-cleavable link.
This improvement over our previous design, in which high-
avidity nanoparticles were restricted by the brain endothelium
(12), should allow for higher brain accumulation of therapeutic
agents contained in nanoparticles from a more practical, sys-
temic dosing amount. The 20Tf-C nanoparticles did not signifi-
cantly differ from the 20Tf-N, indicating that at lower avidity, the
ability to outcompete endogenous Tf for TfR on the blood side
of the BBB is likely the limiting factor for the processes of en-
tering the brain. Despite the increased ability of 200Tf-C nano-
particles to enter the brain, only a 2.7-fold increase in nano-
particle accumulation was observed compared with 200Tf-N.
This is likely because of the cleavage kinetics of the DAK linker.
DAK was chosen because of its good stability at pH 7.4, simple
incorporation into the nanoparticle design, and biologically
compatible cleavage product. The trade-off, however, is slower
cleavage at acidic pH. Radiolabeled-Tf has been observed in the
brain parenchyma within 30 min of systemic injection (21),
suggesting the length of transcytosis is on the order of tens of
minutes. The Tf-DAK-PEG conjugate likely does not cleave
rapidly enough during this period to dissociate all the Tf from
the nanoparticle surface, causing the remaining fraction to limit
entry to the brain. There is certainly room for improvement on
this design, using a linkage with well-controlled cleavage kinetics.
An ideal linker will cleave fully at mildly acidic pH within the
timespan of transcytosis but remain stable at neutral pH long
enough to allow for adequate biodistribution of the nanoparticle.
Unfortunately, there is yet to be a systematic study comparing
pH stability with chemical structure (22).
Unlike Tf-DAK-containing nanoparticles, both Ab-C and
Ab-N formulations have a limited ability to enter the brain in vivo.
These results are consistent with previous reports of high-affinity
anti-TfR Abs trafficking to the lysosome (10, 11, 13). If Ab-TfR
interactions dictate trafficking of the endocytic vesicle, whether
the nanoparticle core is covalently attached to the ligand or a
separate entity should have no effect on the transcytosis capacity.
The mechanism that triggers trafficking to the lysosome, how-
ever, is unclear. Experiments with anti-TfR Abs have suggested
either high-affinity (10) or multivalent binding (11) disrupts TfR
processing. We did not observe the same limitations with high-
avidity, multivalent Tf-containing nanoparticles, which were able
to enter the brain parenchyma, albeit at reduced amounts
compared with lower-avidity nanoparticles. These results suggest
that the native ligand may not adversely affect intracellular
sorting of the targeted therapeutic in the same way or to the
same degree as with Abs. It is well established that Tf disasso-
ciates from TfR at mildly acidic pH (23). Also, the Tf–TfR
Fig. 4. Addition of DAK increases the ability of high-avidity Tf-containing
nanoparticles to enter the brain in vivo. Nanoparticles within the brain
parenchyma were manually counted after silver enhancement of brain
sections. Three BALB/c mice were injected for each formulation. A total of
40 images per mouse brain were analyzed. Median values and SE are
shown. Significant differences are displayed for select group comparisons
(*P < 0.0001). P values for all potential pairwise comparisons are given in SI
Appendix, Table S2.
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complex is known to undergo significant conformational changes
after the pH change (24). It is possible that continuous occupation
of TfR by pH-independent, high-affinity Abs inhibits necessary
conformational changes in the Tf–TfR complex, causing sorting to
the lysosome. The cleavable nanoparticles containing Tf (e.g.,
200Tf-C), however, decrease the influence of the nanoparticle
core on Tf–TfR interactions by physically separating the nano-
particle from the ligand. Thus, Tf sorting may be able to occur
more normally, whereas the rest of the nanoparticle remains a
passenger in the transcytotic vesicle.
The ultimate goal of our work is to develop a safe method to
deliver a wide spectrum of therapeutic agents to the CNS (we have
already translated nanoparticles carrying small-molecule chemo-
therapeutics and siRNAs to the clinic). Although 200Tf-C revealed
the best results here for entering the brain, the amounts achieved
are still on the order of 1% of the injected dose reaching the brain
parenchyma. Whether this quantity is sufficient to deliver enough
therapeutic and/or imaging agent to the brain for practical use is
currently under investigation. As we mentioned previously, we
believe that faster release kinetics could be advantageous to in-
creasing the amounts that reach the brain. Other chemical linkers
that are sensitive to endosomal changes, such as disulfides, may
also benefit from this cleavable ligand strategy, provided they break
rapidly enough during transcytosis.
Here, we show that high-avidity, Tf-containing nanoparticles
are capable of entering the brain parenchyma when Tf is bound
to the nanoparticle through an acid-cleavable link. Exposure to
the decreased pH during the transcytosis process causes the
nanoparticle core to separate from surface Tf bound to TfR and
increases the nanoparticle’s ability to enter the brain paren-
chyma. In contrast, nanoparticles containing anti-TfR Abs were
essentially excluded from the brain independent of the cleavable
link, likely by their trafficking to lysosomes. All Tf-containing
formulations with or without the cleavable link showed a greater
ability to enter the brain than any Ab-containing ones. These
results suggest that TfR-targeted therapeutics using the native
ligand, rather than a high-affinity Ab, may have a greater ability
to cross the BBB. Our results suggest that better understanding
of TfR trafficking within the brain endothelium on a ligand-by-
ligand basis is necessary to develop therapeutics that can readily
engage and be successful in the TfR-mediated transcytosis pro-
cess at the BBB.
Materials and Methods
Complete details of thematerials andmethods used in this study are provided
in SI Appendix.
DSS-DAK-PEG-OPSS Synthesis. N-hydroxysuccinimide-PEG-orthopyridyl disulfide
(NHS-PEG-OPSS) was reacted with DAK to prepare DAK-PEG-OPSS. Unreacted
NHS-PEG-OPSS was quenched by addition of N-(2-aminoethyl)aminomethyl
polystyrene beads for 1 h. Disuccinimidyl suberate (DSS) was added to DAK-
PEG-OPSS to prepare DSS-DAK-PEG-OPSS.
Preparation of Ligand-DAK-PEG-OPSS. Ligand (either Tf or Ab) was added to
DSS-DAK-PEG-OPSS to prepare Ligand-DAK-PEG-OPSS (SI Appendix, Fig. S1 B
and D). High-order PEGylated species were removed by hydrophobic inter-
action chromatography (HIC) to yield a mixture of unreacted ligand and
mono-PEGylated ligand. The amount of ligand-DAK-PEG-OPSS in the mixture
was determined by quantifying OPSS present. The Tf-containing conjugate
was reloaded with iron after HIC by incubating with iron citrate.
Estimation of Ligand-DAK-PEG Stability at pH 5.5. Tf-DAK-PEG was added to
100 mM sodium acetate buffer pH 5.5, 37 °C. At various points, aliquots were
removed, diluted in pH 8 buffer, and frozen on CO2(s) until analysis. Samples
were thawed simultaneously and run on MALDI-TOF, using a sinapinic acid
matrix to determine protein conjugate stability.
Fig. 5. Nanoparticles imaged within the brain after silver enhancement. Nanoparticles were injected i.v. into mice and allowed to circulate for 12 h.
Solid arrows indicate examples of nanoparticles present in the brain parenchyma. Dashed arrows indicate examples of nanoparticles within blood
vessels. The denotation of the formulation is shown in the upper left of each image. All images are to the same scale as shown in the first image at the
top left.
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Preparation of Ligand-PEG-OPSS. Ligand (either Tf or Ab) was added to NHS-
PEG-OPSS to form ligand-PEG-OPSS (SI Appendix, Fig. S1 A and C). Tf-PEG-OPSS
was separated by HPLC followed by HIC to yield a pure, mono-PEGylated
fraction, whereas Ab-PEG-OPSS was purified using only HIC. The Tf-containing
conjugate was reloaded with iron, as described previously.
Preparation of Targeted Nanoparticles. Noncleavable or acid-cleavable
Ligand-PEG conjugates were added to 50-nmAuNPs at the appropriate molar
excess (e.g., 20×mol excess Tf-PEG for 20Tf per particle) for 60 min. An excess
quantity of mPEG-SH was then added for a further 30 min. AuNP’s were
pelleted by centrifugation, resuspended in water, and sonicated for 5 min.
The washing procedure was performed a total of three times.
Dynamic Light Scattering. Particle sizes and zeta potentials were measured
with a Brookhaven Instruments ZetaPALS. Values shown are from an average
of five runs for nanoparticle size and five runs with a target residual of 0.02
for zeta potential.
Nanoparticle Cell-Binding Assay. Increasing quantities of nanoparticles were
added to fixed Neuro2A cells after exposure to either pH 7.4 or pH 5.5 buffer.
The particles were allowed to bind for 90 min, with light mixing every 15 min
to avoid settling. Cells were then washed in PBS three times to remove
unbound nanoparticle and treated with silver enhancement. Bound gold
content was measured by fluorescence in a 96-well plate reader (Tecan
Infinite M200; excitation, 310 nm; emission, 400 nm). The data were fit to a
Langmuir binding isotherm, with Bmax and Kd determined using MATLAB
(Mathworks).
Nanoparticle Transwell Assay. bEnd.3 cells were grown on polyester membrane
transwells (Corning) until transendothelial electrical resistance (TEER) wasmore
than 30 Ohm*cm2. A total of 1 × 1010 AuNPs were added to the apical com-
partment in serum-free DMEM. The entire basal well volume was removed at
various points and replaced with fresh media. An Agilent HP 7500 ICP-MS was
used to measure the gold content of the basal well aliquots.
In Vivo Analysis. All animals were treated according to the NIH guidelines for
animal care and use (25) as approved by the Caltech Institutional Animal Care
and Use Committee. Female BALB/c mice (The Jackson Laboratory) were in-
jected with 4.5 × 1011 particles via lateral tail vein. After 12 h, the mice were
euthanized by CO2 asphyxiation and their brains were resected, bisected, and
fixed in 10% formalin. The brain hemispheres were then embedded in par-
affin, sectioned, deparaffinized, and treated with silver enhancement (Ted
Pella). Sections were counterstained with hematoxylin, mounted, and imaged
using an Olympus IX50 microscope with a 40× objective. Ten images were
acquired randomly from rostral, ventral, and dorsal regions and the cerebel-
lum to give 40 total images per brain. Nanoparticles within the brain paren-
chyma were manually counted. Image acquisition and particle counting was
performed blindly for all slides. Statistical significance for pairwise group
comparisons was tested using the Wilcoxon rank-sum test.
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